Publikationen

Agac, A., Kolbe, S. M., Ludlow, M., Osterhaus, A., Meineke, R., & Rimmelzwaan, G. F. (2023). Host responses to respiratory syncytial virus infection. Viruses, 15(10). https://doi.org/10.3390/v15101999
Details anzeigen

Beicht, J. (2023). Characterization of Langat virus- and vector-based vaccine approaches against tick-borne encephalitis virus. https://elib.tiho-hannover.de/receive/tiho_mods_00009397
Details anzeigen

Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1177324
Details anzeigen

Kubinski, M., Beicht, J., Zdora, I., Biermann, J., Puff, C., Gerlach, T., Tscherne, A., Baumgärtner, W., Osterhaus, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). A recombinant modified vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1182963
Details anzeigen

Kubinski, M., Beicht, J., Zdora, I., Saletti, G., Kircher, M., Petry-Gusmag, M., Steffen, I., Puff, C., Jung, K., Baumgärtner, W., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Prajeeth, C. K. (2023). Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1134371
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. IScience, 26(4). https://doi.org/10.1016/j.isci.2023.106309
Details anzeigen

Nair, N., Osterhaus, A., Rimmelzwaan, G., & Prajeeth, C. K. (2023). Rift Valley fever virus: infection, pathogenesis and host immune responses. Pathogens, 12(9). https://doi.org/10.3390/pathogens12091174
Details anzeigen

Oosting, S. F., van der Veldt, A. A. M., Fehrmann, R. S. N., Bhattacharya, A., van Binnendijk, R. S., GeurtsvanKessel, C. H., Dingemans, A.-M. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., Westphal, T. T., de Wilt, F., Ernst, S. M., Boerma, A., van Zijl, L., Rimmelzwaan, G. F., Kvistborg, P., van Els, C. A. C. M., … de Vries, E. G. E. (2023). Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors. ESMO Open: Cancer Horizons / European Society for Medical Oncology, 8(4). https://doi.org/10.1016/j.esmoop.2023.101599
Details anzeigen

Wilken, L., Stelz, S., Agac, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Recombinant modified vaccinia virus Ankara expressing a glycosylation mutant of dengue virus NS1 induces specific antibody and T-cell responses in mice. Vaccines: Open Access Journal, 11(4). https://doi.org/10.3390/vaccines11040714
Details anzeigen

Wilken, L., Stelz, S., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Transient Blockade of Type I Interferon Signalling Promotes Replication of Dengue Virus Strain D2Y98P in Adult Wild-Type Mice. Viruses, 15(4). https://doi.org/10.3390/v15040814
Details anzeigen

Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1177324
Details anzeigen

Kubinski, M., Beicht, J., Zdora, I., Biermann, J., Puff, C., Gerlach, T., Tscherne, A., Baumgärtner, W., Osterhaus, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). A recombinant modified vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1182963
Details anzeigen

Kubinski, M., Beicht, J., Zdora, I., Saletti, G., Kircher, M., Petry-Gusmag, M., Steffen, I., Puff, C., Jung, K., Baumgärtner, W., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Prajeeth, C. K. (2023). Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1134371
Details anzeigen

Nair, N., Osterhaus, A., Rimmelzwaan, G., & Prajeeth, C. K. (2023). Rift Valley fever virus: infection, pathogenesis and host immune responses. Pathogens, 12(9). https://doi.org/10.3390/pathogens12091174
Details anzeigen

Pilchová, V., Prajeeth, C. K., Jendrny, P., Twele, F., Meller, S., Pink, I., Fathi, A., Addo, M. M., Volk, H. A., Osterhaus, A., Köckritz-Blickwede, M. von, & Schulz, C. (2023). β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: in vitro validation with focus on saliva from COVID-19 patients for scent dog training. Journal of Virological Methods, 317, 114733. https://doi.org/10.1016/j.jviromet.2023.114733
Details anzeigen

Wilken, L., Stelz, S., Agac, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Recombinant modified vaccinia virus Ankara expressing a glycosylation mutant of dengue virus NS1 induces specific antibody and T-cell responses in mice. Vaccines: Open Access Journal, 11(4). https://doi.org/10.3390/vaccines11040714
Details anzeigen

Wilken, L., Stelz, S., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Transient Blockade of Type I Interferon Signalling Promotes Replication of Dengue Virus Strain D2Y98P in Adult Wild-Type Mice. Viruses, 15(4). https://doi.org/10.3390/v15040814
Details anzeigen

Michaely, L. M., Schuwerk, L., Allnoch, L., Schön, K., Waltl, I., Larsen, P.-K., Pavlou, A., Prajeeth, C. K., Rimmelzwaan, G. F., Becker, S. C., Kalinke, U., Baumgärtner, W., & Gerhauser, I. (2022). Intact type I interferon receptor signaling prevents hepatocellular necrosis but not encephalitis in a dose-dependent manner in Rift Valley fever virus infected mice. International Journal of Molecular Sciences, 23(20). https://doi.org/10.3390/ijms232012492
Details anzeigen

Petry, M., Palus, M., Leitzen, E., Mitterreiter, J. G., Huang, B., Kröger, A., Verjans, G. M. G. M., Baumgärtner, W., Rimmelzwaan, G. F., Růžek, D., Osterhaus, A., & Prajeeth, C. K. (2021). Immunity to TBEV related flaviviruses with reduced pathogenicity protects mice from disease but not from TBEV entry into the CNS. Vaccines: Open Access Journal, 9(3: 196). https://doi.org/10.3390/vaccines9030196
Details anzeigen

Kronenberg, J., Pars, K., Brieskorn, M., Prajeeth, C. K., Heckers, S., Schwenkenbecher, P., Skripuletz, T., Pul, R., Pavlou, A., & Stangel, M. (2019). Fumaric acids directly influence gene expression of neuroprotective factors in rodent microglia. International Journal of Molecular Sciences, 20(2: 325). https://doi.org/10.3390/ijms20020325
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. IScience, 26(4). https://doi.org/10.1016/j.isci.2023.106309
Details anzeigen

Meineke, R. (2022). Inhibition of Host Kinase Activity: Effects on Influenza A Virus Infection and Host Cell Signaling. https://elib.tiho-hannover.de/receive/tiho_mods_00007171
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2022). FDA-approved inhibitors of RTK/Raf signaling potently impair multiple steps of in vitro and ex vivo influenza A virus infections. Viruses, 14(9). https://doi.org/10.3390/v14092058
Details anzeigen

Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021). Influenza vaccines: successes and continuing challenges. The Journal of Infectious Diseases, 224(Supplement 4), 405-S419. https://doi.org/10.1093/infdis/jiab269
Details anzeigen

Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021). Aging and options to halt declining immunity to virus infections. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.681449
Details anzeigen

Ricke-Hoch, M., Stelling, E., Lasswitz, L., Gunesch, A. P., Kasten, M., Zapatero-Belinchón, F. J., Brogden, G., Gerold, G., Pietschmann, T., Montiel, V., Balligand, J.-L., Facciotti, F., Hirsch, E., Gausepohl, T., Elbahesh, H., Rimmelzwaan, G. F., Höfer, A., Kühnel, M. P., Jonigk, D., … Hilfiker-Kleiner, D. (2021). Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 16(8). https://doi.org/10.1371/journal.pone.0255335
Details anzeigen

Di, H., Elbahesh, H., & Brinton, M. A. (2020). Characteristics of human OAS1 isoform proteins. Viruses, 12(2: 152). https://doi.org/10.3390/v12020152
Details anzeigen

Meineke, R., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2020). Differential susceptibility of pandemic H1N1 and seasonal H3N2 Influenza A viruses to clinically-approved small molecule kinase inhibitors. In Stiftung Tierärztliche Hochschule Hannover (Ed.), 13th Graduate School Days: 20/21 November 2020 / Stiftung Tierärztliche Hochschule Hannover. Stiftung Tierärztliche Hochschule Hannover.
Details anzeigen

Saletti, G., Gerlach, T., Jansen, J. M., Molle, A., Elbahesh, H., Ludlow, M., Li, W., Bosch, B.-J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2020). Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Scientific Reports, 10: 21447. https://doi.org/10.1038/s41598-020-78506-9
Details anzeigen

Bergmann, S., & Elbahesh, H. (2019). Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology, 534, 54–63. https://doi.org/10.1016/j.virol.2019.05.020
Details anzeigen